Greenwich Lifesciences Inc

GLSI remains entrenched in a Stage 4 decline following a decisive Support Failure. Price is extended into extreme oversold conditions but has only staged a bounce up to yet-unretested overhead EMAs. The medium-term bias is bearish, and preferred execution is deferred sell-side engagement on rallies into the declining 9/21 EMAs and 50 DMA rather than chasing current weakness.

• ↑European approval for GP2 in Phase III FLAMINGO-01 trial announced Jul 2026 drives stock catalyst
• ↑Momentum factor indicates strong price trends, fueling investor interest
• ↓Volatility multiplier of 4.53 signals extreme price swings deterring risk-averse investors